Ensign Peak Advisors
IMVT icon

Ensign Peak Advisors’s Immunovant IMVT Stock Holding History

Ensign Peak Advisors’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$201K Sell
5,206
-1,400
-21% -$42.7K ﹤0.01% 1378
2026
Q1 		$164K Hold
6,606
– – ﹤0.01% 1405
2025
Q4 		$168K Sell
6,606
-15,700
-70% -$350K ﹤0.01% 1387
2025
Q3 		$360K Sell
22,306
-6,100
-21% -$98.8K ﹤0.01% 1521
2025
Q2 		$454K Hold
28,406
– – ﹤0.01% 1582
2025
Q1 		$485K Buy
28,406
+8,700
+44% +$182K ﹤0.01% 1562
2024
Q4 		$488K Sell
19,706
-138,915
-88% -$3.94M ﹤0.01% 1602
2024
Q3 		$4.52M Sell
158,621
-45,600
-22% -$1.34M 0.01% 654
2024
Q2 		$5.39M Buy
204,221
+37,165
+22% +$1.06M 0.01% 604
2024
Q1 		$5.4M Sell
167,056
-994
-0.6% -$36.3K 0.01% 615
2023
Q4 		$7.08M Buy
168,050
+20,700
+14% +$762K 0.01% 536
2023
Q3 		$5.66M Buy
+147,350
New +$3.33M 0.01% 532
2022
Q4 		– Sell
-6,350
Closed -$35K – 1985
2022
Q3 		$35K Buy
6,350
+2,670
+73% +$13.1K ﹤0.01% 2264
2022
Q2 		$14K Hold
3,680
– – ﹤0.01% 2140
2022
Q1 		$20K Hold
3,680
– – ﹤0.01% 2180
2021
Q4 		$31K Buy
+3,680
New +$30.4K ﹤0.01% 2166

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Ensign Peak Advisors's IMVT Position: Q2 2026 in Review

Ensign Peak Advisors reduced its Immunovant (IMVT) stake by 21% in Q2 2026, selling an estimated $42.7K and leaving 5,206 shares worth $201K. The position accounts for ﹤0.01% of the portfolio, ranked #1378.

Ensign Peak Advisors first reported a position in IMVT in Q4 2021 and has held it in 16 quarters since. The position peaked at $7.08M in Q4 2023. 227 funds tracked by Wall St. Rank hold IMVT as of Q2 2026.

  • Ensign Peak Advisors held 5,206 shares of Immunovant worth $201K as of Q2 2026.
  • Ensign Peak Advisors sold 1,400 Immunovant shares in Q2 2026, an estimated $42.7K.
  • Immunovant made up ﹤0.01% of Ensign Peak Advisors's portfolio in Q2 2026, its #1378 holding.
  • Ensign Peak Advisors first reported a position in Immunovant in Q4 2021 and has held it in 16 quarters since.
  • Ensign Peak Advisors's Immunovant position peaked at $7.08M in Q4 2023.
  • 227 funds tracked by Wall St. Rank held Immunovant as of Q2 2026.

Based on Ensign Peak Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.